CN108421050A - MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation - Google Patents
MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation Download PDFInfo
- Publication number
- CN108421050A CN108421050A CN201710080783.2A CN201710080783A CN108421050A CN 108421050 A CN108421050 A CN 108421050A CN 201710080783 A CN201710080783 A CN 201710080783A CN 108421050 A CN108421050 A CN 108421050A
- Authority
- CN
- China
- Prior art keywords
- retina
- tert
- choroidal neovascularization
- microrna
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
Abstract
The present invention relates to microRNA interference reverse transcriptase of telomere plasmids to inhibit retina, choroidal neovascularization novel formulation, is mainly used in medical domain, the prevention and control and treatment of ophthalmology retina, choroidal neovascularization.Currently, retinal neovascularization Biological Pharmacotherapy is mainly the treatment of anti-vegf target molecule, action time is shorter, easily recurs.Therefore, it is necessary to seek other potential treatment targets from molecule and gene level, the generation that more efficient method treats and prevents retinal neovascularization is found.1. the present invention with reverse transcriptase of telomere (TERT) be target spot, with microRNA（siRNA）Based on interference, lowered by the expression of TERT protein in TERT interferential RNAs retina, choroidal neovascularization, reduce retina, choroidal neovascularization endothelial cell telomerase activation and inhibit the proliferation of retina, choroidal neovascularization endothelial cell.The design of 2.siRNA and the structure of plasmid.SiRNA action target spots, chemical synthesis are designed according to the mRNA sequence of TERT genes in gene pool.
Description
Technical field
In medical domain, the prevention and control and treatment of ophthalmology retina, choroidal neovascularization.
Background technology
Retinal neovascularization be found in diabetic retinopathy, retinal vein obstruction, retinopathy of prematurity,
A variety of eye disease such as retinal phlebitis, it is very harmful to eyesight or even eyesight can be caused to completely lose.And currently, retina is newborn
Blood vessel Biological Pharmacotherapy is mainly the treatment of anti-vegf target molecule, mainly anti-including VEGF oligomeric deoxynucleotides, VEGF
Body, RNA interference VEGF drugs etc., action time is shorter, easily recurs.So being highly desirable at present from molecule and gene level
Other potential treatment targets are sought, the generation that more efficient method treats and prevents retinal neovascularization is found.
Invention content
It is now recognized that reverse transcriptase of telomere is the major regulatory subunit of telomerase activation.Telomerase and blood vessel endothelium
Cell Proliferation is closely related, is formed to new vessels and the stability of blood vessel endothelium is maintained to play an important role.1. the present invention with
Reverse transcriptase of telomere (telomerase reverse transcription, TERT) is target spot, with microRNA
（Small interference RNA, siRNA）Based on interference, pass through TERT interferential RNAs retina, the new green blood of choroid
The expression of TERT protein is lowered in pipe, reduces retina, the telomerase activation of choroidal neovascularization endothelial cell and inhibition
The proliferation of retina, choroidal neovascularization endothelial cell reaches the treatment effect for inhibiting retina, choroidal neovascularization to be formed
Fruit.2. the design of siRNA and the structure of plasmid.Target is acted on according to the mRNA sequence design siRNA of TERT genes in gene pool
Point, chemical synthesis.
Claims (1)
1. microRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation, it is mainly used for
In medical domain, the prevention and control and treatment of ophthalmology retina, choroidal neovascularization.Its feature has：The present invention is reversed with Telomerase
It is target spot to record enzyme (telomerase reverse transcription, TERT), with microRNA（small
Interference RNA, siRNA）Based on interference, pass through TERT protein in TERT interferential RNA retinal neovascularizations
Expression lower, reduce retinal neovascularization endothelial cell telomerase activation simultaneously inhibit retinal neovascularization endothelial cell
Proliferation, reach inhibit retinal neovascularazation therapeutic effect；The design of siRNA and the structure of plasmid, according to base
Because the mRNA sequence of TERT genes in library designs siRNA action target spots, chemical synthesis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080783.2A CN108421050A (en) | 2017-02-15 | 2017-02-15 | MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080783.2A CN108421050A (en) | 2017-02-15 | 2017-02-15 | MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108421050A true CN108421050A (en) | 2018-08-21 |
Family
ID=63155242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710080783.2A Pending CN108421050A (en) | 2017-02-15 | 2017-02-15 | MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108421050A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533858A (en) * | 2010-12-27 | 2012-07-04 | 郑州威瑞生物技术有限公司 | Tumor-specific replication-competent adenovirus anti-tumor preparation |
| CN105848667A (en) * | 2013-11-22 | 2016-08-10 | 杰姆维克斯&凯尔有限公司 | Peptide having angiogenesis inhibitory activity and composition containing same |
-
2017
- 2017-02-15 CN CN201710080783.2A patent/CN108421050A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533858A (en) * | 2010-12-27 | 2012-07-04 | 郑州威瑞生物技术有限公司 | Tumor-specific replication-competent adenovirus anti-tumor preparation |
| CN105848667A (en) * | 2013-11-22 | 2016-08-10 | 杰姆维克斯&凯尔有限公司 | Peptide having angiogenesis inhibitory activity and composition containing same |
Non-Patent Citations (2)
| Title |
|---|
| 闵晓洁 等，: "TERT基因siRNA抑制鼠视网膜新生血管形成的研究", 《中华眼科杂志》 * |
| 闵晓洁: "端粒酶活性表达的调控对视网膜新生血管形成影响的实验研究", 《青岛大学博士论文》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pikaard et al. | A transcription fork model for pol IV and pol v–dependent RNA-directed DNA methylation | |
| JP2018520149A (en) | CRISPR / CAS9 based treatment | |
| CN112007044B (en) | Medicine for preventing oxidative stress of retinal ganglion cells and wet macular degeneration | |
| WO2004042024B1 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA | |
| Yamaguchi et al. | Rho-kinase/ROCK as a potential drug target for vitreoretinal diseases | |
| JP2006520611A5 (en) | ||
| CA2687079A1 (en) | Methods of treatment of skin ulcers | |
| RU2008136655A (en) | VEGF RECEPTOR HYBRID PROTEINS, THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USE FOR EYE DISEASES | |
| Mizutani et al. | Nucleoside reverse transcriptase inhibitors suppress laser-induced choroidal neovascularization in mice | |
| Wang et al. | miRNA involvement in angiogenesis in age-related macular degeneration | |
| Zhang et al. | Overexpression of microRNA-146 protects against oxygen-glucose deprivation/recovery-induced cardiomyocyte apoptosis by inhibiting the NF-κB/TNF-α signaling pathway | |
| Tan et al. | Gene-based therapeutics for acquired retinal disease: opportunities and progress | |
| Yang et al. | Inhibitory effects of polysaccharide extract from Spirulina platensis on corneal neovascularization | |
| Shimizu et al. | Caveolin-1 promotes cellular senescence in exchange for blocking subretinal fibrosis in age-related macular degeneration | |
| CN108421050A (en) | MicroRNA interferes reverse transcriptase of telomere plasmid to inhibit retina, choroidal neovascularization novel formulation | |
| Lin et al. | Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro | |
| JP2023144029A (en) | Sirna and their use in methods and compositions for inhibiting expression of nrarp gene | |
| Hwang et al. | Transforming Growth Factor-β1–induced Human Subconjunctival Fibrosis is Mediated by MicroRNA 143/145 Expression | |
| US8217163B2 (en) | Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas | |
| Peng et al. | The effects of small interfering RNA–targeting tissue factor on an in vitro model of neovascularization | |
| CN113117086A (en) | Methods, formulations and uses for modulating the complement system | |
| Ameri et al. | Reduced expression of vegf-a in human retinal pigment epithelial cells and human muller cells following CRISPR-Cas9 ribonucleoprotein-mediated gene disruption | |
| CN109498620A (en) | A kind of drug for treating glaucoma | |
| CN108309978A (en) | EZH2 inhibitor prevents preparing or treats with the application in the drug of angiocardiopathy caused by vascular smooth muscle cell curing | |
| WO2020258078A1 (en) | Rna-directed editing-based method for inhibiting choroidal neovascularization, and reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180821 |